Krystal Biotech FY2026 EPS Forecast Lifted by HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Krystal Biotech in a research note issued to investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $7.02 per share for the year, up from their previous forecast of $6.47. HC Wainwright has a “Buy” rating and a $221.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the firm posted ($0.67) EPS. The company’s quarterly revenue was up 879.9% on a year-over-year basis.

KRYS has been the topic of a number of other reports. Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday. Chardan Capital boosted their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Evercore ISI lifted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Trading Up 5.0 %

Shares of KRYS opened at $183.09 on Wednesday. The firm’s fifty day simple moving average is $181.39 and its two-hundred day simple moving average is $180.25. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The stock has a market capitalization of $5.26 billion, a P/E ratio of 103.44 and a beta of 0.82.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Janney Montgomery Scott LLC purchased a new stake in shares of Krystal Biotech in the first quarter worth approximately $3,175,000. Swiss National Bank raised its position in Krystal Biotech by 0.8% in the 1st quarter. Swiss National Bank now owns 36,200 shares of the company’s stock valued at $6,441,000 after buying an additional 300 shares during the last quarter. Sei Investments Co. lifted its stake in Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after acquiring an additional 18,968 shares in the last quarter. Headlands Technologies LLC purchased a new position in Krystal Biotech during the 1st quarter worth $291,000. Finally, ProShare Advisors LLC grew its stake in shares of Krystal Biotech by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 5,865 shares of the company’s stock worth $1,044,000 after acquiring an additional 486 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 14.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).